Real-life data on efficacy and safety of original Adalimumab and biosimilar Adalimumab (ABP 501) in pediatric rheumatic diseases

References

• Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with Adalimumab plus methotrexate versus methotrexate alone or Adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26–37.
   PubMed Web of Science ®Google Scholar
• Horneff G, Seyger MMB, Arikan D, et al. Safety of Adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriasis, and crohn’s disease. J Pediatr. 2018;201:166–175.e3.
   PubMed Web of Science ®Google Scholar
• Petty RE, Laxer RM, Wedderburn LR. Juvenile idiopathic arthritis: classification and basic concepts. In: Petty RE, Laxer RM, Lindsley CB, et al., editors. Textbook of Pediatric Rheumatology. 8th edn ed. Philadelphia: Elsevier; 2021. p. 209–215.
   Google Scholar
• Ringold S, Angeles-Han ST, Beukelman T, et al. American college of Rheumatology/Arthritis foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res (Hoboken). 2019;71(6):717–734.
   PubMed Web of Science ®Google Scholar
• Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Clin Immunol. 2020;211:108322.
   PubMed Web of Science ®Google Scholar
• Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and Adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian registry [published correction appears in. J Rheumatol. 2013 Jan;40(1):74–79. 106.
   PubMed Web of Science ®Google Scholar
• Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res. 2011;3:29–36.
   PubMedGoogle Scholar
• St Clair-Jones A, Prignano F, Goncalves J, et al. Understanding and minimising injection-site pain following subcutaneous administration of biologics: a narrative review. Rheumatol Ther. 2020;7(4):741–757.
   PubMed Web of Science ®Google Scholar
• Zhou X, Chen Z, Bi X. An update review of biosimilars of Adalimumab in Psoriasis - bioequivalence and interchangeability. Drug Des Devel Ther. 2021 Published Jul 8;15:2987–2998.
   PubMed Web of Science ®Google Scholar
• Zhao S, Chadwick L, Mysler E, et al. Review of biosimilar trials and data on Adalimumab in rheumatoid arthritis. Curr Rheumatol Rep. 2018;20(10):57.
   PubMed Web of Science ®Google Scholar
• Ricceri F, Rosi E, Di Cesare A, et al. Clinical experience with Adalimumab biosimilar imraldi in hidradenitis suppurativa. Dermatol Ther. 2020;33(6):e14387.
   PubMed Web of Science ®Google Scholar
• Di Cesare A, Tronconi G, Fastame TM, et al. SB5 Adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis. Dermatol Ther. 2020;33(3):e13435.
   PubMed Web of Science ®Google Scholar
• Velayudhan J, Chen YF, Rohrbach A, et al. Demonstration of functional similarity of proposed biosimilar ABP 501 to Adalimumab. BioDrugs. 2016;30(4):339–351.
   PubMed Web of Science ®Google Scholar
• Demirkan FG, Ulu K, Öztürk K, et al. Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group [published online ahead of print, 2021 Nov 16]. Expert Opin Biol Ther. 2022;22(2):197–202.
   PubMed Web of Science ®Google Scholar
• Trincianti C, Van Dijkhuizen EHP, Alongi A, et al. Definition and validation of the American college of rheumatology 2021 juvenile arthritis disease activity score cutoffs for disease activity states in juvenile idiopathic arthritis. Arthritis Rheumatol. 2021;73(11):1966–1975.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516.
   PubMed Web of Science ®Google Scholar
• Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, edmonton, 2001. J Rheumatol. 2004;31(2):390–392.
   PubMed Web of Science ®Google Scholar
• Trincianti C, Van Dijkhuizen EHP, Alongi A, et al. Definition and validation of the American college of rheumatology 2021 juvenile arthritis disease activity score cutoffs for disease activity states in juvenile idiopathic arthritis. Arthritis Rheumatol. 2021;73(11):1966–1975.
   PubMed Web of Science ®Google Scholar
• [updated 2018 Mar 09]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
   Google Scholar
• Bruni C, Gentileschi S, Pacini G, et al. The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases. Ther Adv Musculoskelet Dis. 2020 Published Oct 13;12:1759720X20964031.
   PubMed Web of Science ®Google Scholar
• Bruni C, Bitti R, Nacci F, et al. Efficacy and safety of switching from reference Adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases. Clin Rheumatol. 2021;40(1):85–91.
   PubMed Web of Science ®Google Scholar
• Kay J, Jaworski J, Wojciechowski R, et al. Efficacy and safety of biosimilar CT-P17 versus reference Adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. Arthritis Res Ther. 2021 Published Feb 5;23(1):51.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Glover J, Greenwald M, et al. FKB327, an Adalimumab biosimilar, versus the reference product: results of a randomized, phase III, double-blind study, and its open-label extension. Arthritis Res Ther. 2019 Published Dec 12;21(1):281.
   PubMed Web of Science ®Google Scholar
• Maccora I, Lombardı N, Crescıolı G, et al. OBSIDIAn-real-world evidence of originator to BioSImilar drug switch in juvenile idiopathic arthritis. Rheumatology (Oxford). 2021 Jul 17;61(4) :1518–1528.
   Web of Science ®Google Scholar
• Thiele F, Klein A, Hospach A, et al. Efficacy and safety of etanercept biosimilars compared with the originator for treatment of juvenile arthritis: a prospective observational study. ACR Open Rheumatol. 2021;3(11):779–787.
   PubMedGoogle Scholar
• Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376(17):1637–1646.
   PubMed Web of Science ®Google Scholar
• Quartier P, Baptiste A, Despert V, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of Adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2018;77(7):1003–1011.
   PubMed Web of Science ®Google Scholar
• Sözeri B, Kardeş E, Salı E, et al. Drug survival of the infliximab biosimilar (CT-P13) in paediatric patients with non-infectious uveitis. Clin Exp Rheumatol. 2021;39(4):907–912.
   PubMed Web of Science ®Google Scholar
• Huizinga TWJ, Torii Y, Muniz R. Adalimumab biosimilars in the treatment of rheumatoid arthritis: a systematic review of the evidence for biosimilarity. Rheumatol Ther. 2021;8(1):41–61.
   PubMed Web of Science ®Google Scholar